BRAF and melanoma: In a retrospective study of 161 patients with stage III melanoma and no radiological evidence of disease, detection of BRAF/NRAS mutant ctDNA (by ddPCR) at a single timepoint within 12 weeks of surgery was associated with poor outcome (disease-free Interval (DFI); HR 3.12; 95% CI 1.79–5.47; P < 0.0001, distant metastasis-free interval (DMFI); HR 3.22; 95% CI 1.80–5.79; P < 0.0001, OS HR 2.63; 95% CI 1.40–4.96; P = 0.003) [15••].